Atiyatum Billah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Atiyatum Billah has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Arga Setyo Adji
Universitas Airlangga
4 shared publications Abdillah Maulana Satrioaji
Faculty of Medicine, Universitas Hang Tuah Fakultas Kedokteran, Surabaya, East Java, 60228
1 shared publication- Abdillah Maulana Satrioaji
Faculty of Medicine Hang Tuah University Surabaya East Java Indonesia
1 shared publication - Angela Puspita
Emergency Medicine Division, Department of Internal Medicine Hang Tuah University Surabaya East Java Indonesia
1 shared publication - Angga Nugraha
Department of Cardiology, Gadjah Mada University, Yogyakarta, Center Java, Indonesia Yogyakarta Center Java Indonesia
1 shared publication - Antonius Dwi Saputra
Faculty of Medicine, Universitas Jember, East Java, 68121
1 shared publication
Latest Publications
- Open Access
- 26 August 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 823
Long-Term Outcomes of Crush versus Culotte Stenting in Coronary Bifurcation Lesions: A Systematic Review and Network Meta-Analysis
Introduction Coronary bifurcation lesions (CBL) represent a challenging subset in percutaneous coronary intervention, often necessitating complex stenting strategies. Among these, Crush and Culotte techniques are widely employed; however, their long-term comparative effectiveness remains debated. Methods This systematic review and network meta-analysis aimed to evaluate one-, three-, and five-year clinical outcomes of Crush versus Culotte stenting techniques in patients with CBL. Results This meta-analysis included 13 articles involving 3,777 patients with coronary bifurcation lesions, with a mean age of 65.93 ± 4.67 years. At the one-year follow-up, Culotte stenting showed better outcomes in reducing target lesion revascularization and target vessel revascularization, with significant differences observed in TVR (RR 2.22; 95% CI: 0.40–12.38, p=0.0014) and TLR (RR 1.14; 95% CI: 0.30–4.37, p=0.0225), favoring Culotte. However, by the three-year follow-up, Crush stenting demonstrated superior effectiveness, showing lower risks of TVR (RR 0.62; 95% CI: 0.36–1.10, p=0.0105) and TLR (RR 0.68; 95% CI: 0.38–1.21, p=0.0284). No significant differences were observed between Crush and Culotte in myocardial infarction, stent thrombosis, cardiac death, or coronary artery bypass grafting (CABG). SUCRA analysis revealed that DK Crush ranked highest for reducing TVR (RR 0.39; 95% CI: 0.27–0.57; SUCRA 0.99), Nano Crush for TLR (RR 0.11; 95% CI: 0.01–2.04; SUCRA 0.89), DK Crush for ST (RR 0.23; 95% CI: 0.05–1.08; SUCRA 0.86), Mini Crush for MI (RR 0.23; 95% CI: 0.03–1.73; SUCRA 0.78), Nano Crush for CD (RR 0.26; 95% CI: 0.03–2.18; SUCRA 0.84), and Typical Crush for CABG (RR 0.74; 95% CI: 0.29–1.88; SUCRA 0.82). Conclusion DK Crush stenting demonstrated superior long-term efficacy over Culotte, particularly in reducing TLR and TVR at three years. While differences in other outcomes were not statistically significant, SUCRA analysis supports DK Crush as the preferred strategy for complex bifurcation PCI.
- 26 August 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 823
Open AccessLong-Term Outcomes of Crush versus Culotte Stenting in Coronary Bifurcation Lesions: A Systematic Review and Network Meta-Analysis
Introduction Coronary bifurcation lesions (CBL) represent a challenging subset in percutaneous coronary intervention, often necessitating complex stenting strategies. Among these, Crush and Culotte techniques are widely employed; however, their long-term comparative effectiveness remains debated. Methods This systematic review and network meta-analysis aimed to evaluate one-, three-, and five-year clinical outcomes of Crush versus Culotte stenting techniques in patients with CBL. Results This meta-analysis included 13 articles involving 3,777 patients with coronary bifurcation lesions, with a mean age of 65.93 ± 4.67 years. At the one-year follow-up, Culotte stenting showed better outcomes in reducing target lesion revascularization and target vessel revascularization, with significant differences observed in TVR (RR 2.22; 95% CI: 0.40–12.38, p=0.0014) and TLR (RR 1.14; 95% CI: 0.30–4.37, p=0.0225), favoring Culotte. However, by the three-year follow-up, Crush stenting demonstrated superior effectiveness, showing lower risks of TVR (RR 0.62; 95% CI: 0.36–1.10, p=0.0105) and TLR (RR 0.68; 95% CI: 0.38–1.21, p=0.0284). No significant differences were observed between Crush and Culotte in myocardial infarction, stent thrombosis, cardiac death, or coronary artery bypass grafting (CABG). SUCRA analysis revealed that DK Crush ranked highest for reducing TVR (RR 0.39; 95% CI: 0.27–0.57; SUCRA 0.99), Nano Crush for TLR (RR 0.11; 95% CI: 0.01–2.04; SUCRA 0.89), DK Crush for ST (RR 0.23; 95% CI: 0.05–1.08; SUCRA 0.86), Mini Crush for MI (RR 0.23; 95% CI: 0.03–1.73; SUCRA 0.78), Nano Crush for CD (RR 0.26; 95% CI: 0.03–2.18; SUCRA 0.84), and Typical Crush for CABG (RR 0.74; 95% CI: 0.29–1.88; SUCRA 0.82). Conclusion DK Crush stenting demonstrated superior long-term efficacy over Culotte, particularly in reducing TLR and TVR at three years. While differences in other outcomes were not statistically significant, SUCRA analysis supports DK Crush as the preferred strategy for complex bifurcation PCI.
- Open Access
- 8 May 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (3) , e70073
Long‐term of epicardial radiofrequency ablation and benefit for recurrent ventricular arrhythmia in Brugada syndrome: A systematic review and meta‐analysis
Background: Brugada syndrome (BrS) is a rare cardiac channelopathy linked to an increased risk of ventricular arrhythmias (VA) and sudden cardiac death. Radiofrequency ablation (RFA), particularly epicardial ablation, is recommended for BrS patients with recurrent VA unresponsive to conventional treatments like implantable cardioverter‐defibrillators (ICD) and quinidine. This study aims to evaluate the long‐term efficacy of epicardial RFA in preventing VA recurrence in BrS.Methods: A systematic search of PubMed, ScienceDirect, Cochrane Library, and ProQuest databases was conducted following PRISMA 2020 guidelines. Studies on RFA for VA in BrS were included. Primary outcomes were VA recurrence and all‐cause mortality. Statistical analysis was performed using Review Manager 5.4.Results: Epicardial, endocardial, and combined ablation strategies effectively reduced VA recurrence, decreased ICD shocks, and improved clinical outcomes in BrS. Epicardial ablation RFA near coronary arteries showed a notable reduction in VA recurrence, while endocardial ablation remained a viable alternative. Meta‐analysis revealed a significant reduction in VA recurrence (RR 0.17; 95% CI 0.07–0.43; p < .0001) and ICD shocks (RR 0.13; 95% CI 0.04–0.44; p = .001). Subgroup analysis suggested greater VA reduction with epicardial ablation, though without statistical significance.Conclusion: Epicardial RFA is associated with a significant reduction in recurrent VAs (83%) and ICD shock rates (87%) in patients with BrS. The procedure demonstrates a favorable long‐term safety profile, with no mortality reported in the included studies.
- 8 May 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (3) , e70073
Open AccessLong‐term of epicardial radiofrequency ablation and benefit for recurrent ventricular arrhythmia in Brugada syndrome: A systematic review and meta‐analysis
Background: Brugada syndrome (BrS) is a rare cardiac channelopathy linked to an increased risk of ventricular arrhythmias (VA) and sudden cardiac death. Radiofrequency ablation (RFA), particularly epicardial ablation, is recommended for BrS patients with recurrent VA unresponsive to conventional treatments like implantable cardioverter‐defibrillators (ICD) and quinidine. This study aims to evaluate the long‐term efficacy of epicardial RFA in preventing VA recurrence in BrS.Methods: A systematic search of PubMed, ScienceDirect, Cochrane Library, and ProQuest databases was conducted following PRISMA 2020 guidelines. Studies on RFA for VA in BrS were included. Primary outcomes were VA recurrence and all‐cause mortality. Statistical analysis was performed using Review Manager 5.4.Results: Epicardial, endocardial, and combined ablation strategies effectively reduced VA recurrence, decreased ICD shocks, and improved clinical outcomes in BrS. Epicardial ablation RFA near coronary arteries showed a notable reduction in VA recurrence, while endocardial ablation remained a viable alternative. Meta‐analysis revealed a significant reduction in VA recurrence (RR 0.17; 95% CI 0.07–0.43; p < .0001) and ICD shocks (RR 0.13; 95% CI 0.04–0.44; p = .001). Subgroup analysis suggested greater VA reduction with epicardial ablation, though without statistical significance.Conclusion: Epicardial RFA is associated with a significant reduction in recurrent VAs (83%) and ICD shock rates (87%) in patients with BrS. The procedure demonstrates a favorable long‐term safety profile, with no mortality reported in the included studies.
- Open Access
- 1 January 2022
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 10 (F) , 305-313
A review of Leaves and Seeds Moringa oleifera Extract: The potential Moringa oleifera as Antibacterial, Anti-Inflammatory, Antidiarrhoeal, And Antiulcer Approaches To Bacterial Gastroenteritis
BACKGROUND: Bacterial gastroenteritis is a disease in the tropics in the form of inflammation of the stomach and intestines due to several bacteria, such as Salmonella, Campylobacter, Shigella, Escherichia coli, Vibrio, Yersinia, and Listeria with symptoms of diarrhea without or with vomiting and frequent fever. Gastroenteritis is a global disease with the highest prevalence in the agricultural community, especially farmers and fishermen. AIM: This research is to determine the potential of leaf and seed extract Moringa oleifera as an alternative therapy for bacterial gastroenteritis. METHODS: A literature review approach derived from the analysis and synthesis of various related references is used. The author selects journals full text and books published in the last ten years maximum through several databases, namely PubMed, Google Scholar, ScienceDirect, and Cochrane with the keywords: diarrhea, gastroenteritis, antibacterial, antiulcer, anti-inflammation, and M. oleifera. RESULTS: Seed and leaf extract M. oleifera played a role in preventing some of the effects of the pathogenesis of diarrhea due to bacterial infection. Methanol, N-hexane, ethyl acetate, flavonoids, phenols, saponins, alkaloids, tannins, and steroids from seed and leaf extract M. oleifera have antibacterial effects. The content of quercetin has an anti-inflammatory effect. The content of tannins, flavonoids, and alkaloids has antidiarrheal activity. The content of ethanol and tannins has an antiulcer effect. This potential can help cure patients with bacterial gastroenteritis. CONCLUSION: Leaf and seed extract of M. oleifera has good antibacterial, anti-inflammatory, antiulcer, and antidiarrheal potential for the treatment of bacterial gastroenteritis.
- 1 January 2022
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 10 (F) , 305-313
Open AccessA review of Leaves and Seeds Moringa oleifera Extract: The potential Moringa oleifera as Antibacterial, Anti-Inflammatory, Antidiarrhoeal, And Antiulcer Approaches To Bacterial Gastroenteritis
BACKGROUND: Bacterial gastroenteritis is a disease in the tropics in the form of inflammation of the stomach and intestines due to several bacteria, such as Salmonella, Campylobacter, Shigella, Escherichia coli, Vibrio, Yersinia, and Listeria with symptoms of diarrhea without or with vomiting and frequent fever. Gastroenteritis is a global disease with the highest prevalence in the agricultural community, especially farmers and fishermen. AIM: This research is to determine the potential of leaf and seed extract Moringa oleifera as an alternative therapy for bacterial gastroenteritis. METHODS: A literature review approach derived from the analysis and synthesis of various related references is used. The author selects journals full text and books published in the last ten years maximum through several databases, namely PubMed, Google Scholar, ScienceDirect, and Cochrane with the keywords: diarrhea, gastroenteritis, antibacterial, antiulcer, anti-inflammation, and M. oleifera. RESULTS: Seed and leaf extract M. oleifera played a role in preventing some of the effects of the pathogenesis of diarrhea due to bacterial infection. Methanol, N-hexane, ethyl acetate, flavonoids, phenols, saponins, alkaloids, tannins, and steroids from seed and leaf extract M. oleifera have antibacterial effects. The content of quercetin has an anti-inflammatory effect. The content of tannins, flavonoids, and alkaloids has antidiarrheal activity. The content of ethanol and tannins has an antiulcer effect. This potential can help cure patients with bacterial gastroenteritis. CONCLUSION: Leaf and seed extract of M. oleifera has good antibacterial, anti-inflammatory, antiulcer, and antidiarrheal potential for the treatment of bacterial gastroenteritis.
- Open Access
- 1 January 2022
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 10 (F) , 1-6
A Systematic Review and Meta-analysis of Randomized Placebo-controlled Trials 1 Year after Starting Sodium-glucose Transporter-2 Inhibitors in Heart Failure Patients with Reduced Ventricular Ejection Fraction
Introduction: The Sodium-Glucose Cotransporter-2 Inhibitor (SGLT-2 inhibitor) is a diabetic medication. Recently, there has been enough evidence of SGLT-2 inhibitors in type 2 diabetes mellitus, driving in an abatement in cardiovascular breakdown hospitalization. To explore SGLT-2 inhibitor in cardiovascular breakdown with lower discharge portion, we led an orderly survey and meta-examination. Strategies: We played out a methodical writing search from various electronic databases. We used keywords:” SGLT-2 inhibitor '' and “Heart Failure.” Inclusion criteria are randomized placebo-controlled trial, one-year follow-up and ejection fraction 40% or less. Composite endpoint is cardiovascular mortality with hospitalization of heart failure. Individual outcomes include all-cause mortality, cardiovascular passing, and cardiovascular breakdown hospitalization. For low heterogeneity scores, results are introduced utilizing a danger proportion (RR) with a 95 percent certainty stretch and statistical analysis using a fixed-effect model. Results: Total of two randomized control trial was selected (DAPA-HF [Dapagliflozin] and EMPEROR-Reduced [Empagliflozin]) with 8,474 patients pooled within our analysis. The results of the composite outcome compared SGLT-2 inhibitor with placebo had significant decrease in the composite of cardiovascular passing with hospitalization of cardiovascular breakdown (RR=0.78 [95% CI, 0.71–0.84], p<0.00001; I2=0%). Result of individual outcome showed significant reduction of all-cause mortality (RR=0.88 [95% CI, 0.79 – 0.98], p=0.03; I2=1%), cardiovascular mortality (RR=0.87 [95% CI, 0.77 – 0.99], p=0.03; I2=0%) and hospitalization of heart failure (RR=0.72 [95% CI, 0.65–0.81], p<0.00001; I2=0%). Conclusion: Within one year of treatment with an SGLT-2 inhibitor, the composite of cardiovascular passing with cardiovascular breakdown hospitalization, all-cause mortality, cardiovascular mortality, and cardiovascular breakdown hospitalization was significantly reduced.
- 1 January 2022
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 10 (F) , 1-6
Open AccessA Systematic Review and Meta-analysis of Randomized Placebo-controlled Trials 1 Year after Starting Sodium-glucose Transporter-2 Inhibitors in Heart Failure Patients with Reduced Ventricular Ejection Fraction
Introduction: The Sodium-Glucose Cotransporter-2 Inhibitor (SGLT-2 inhibitor) is a diabetic medication. Recently, there has been enough evidence of SGLT-2 inhibitors in type 2 diabetes mellitus, driving in an abatement in cardiovascular breakdown hospitalization. To explore SGLT-2 inhibitor in cardiovascular breakdown with lower discharge portion, we led an orderly survey and meta-examination. Strategies: We played out a methodical writing search from various electronic databases. We used keywords:” SGLT-2 inhibitor '' and “Heart Failure.” Inclusion criteria are randomized placebo-controlled trial, one-year follow-up and ejection fraction 40% or less. Composite endpoint is cardiovascular mortality with hospitalization of heart failure. Individual outcomes include all-cause mortality, cardiovascular passing, and cardiovascular breakdown hospitalization. For low heterogeneity scores, results are introduced utilizing a danger proportion (RR) with a 95 percent certainty stretch and statistical analysis using a fixed-effect model. Results: Total of two randomized control trial was selected (DAPA-HF [Dapagliflozin] and EMPEROR-Reduced [Empagliflozin]) with 8,474 patients pooled within our analysis. The results of the composite outcome compared SGLT-2 inhibitor with placebo had significant decrease in the composite of cardiovascular passing with hospitalization of cardiovascular breakdown (RR=0.78 [95% CI, 0.71–0.84], p<0.00001; I2=0%). Result of individual outcome showed significant reduction of all-cause mortality (RR=0.88 [95% CI, 0.79 – 0.98], p=0.03; I2=1%), cardiovascular mortality (RR=0.87 [95% CI, 0.77 – 0.99], p=0.03; I2=0%) and hospitalization of heart failure (RR=0.72 [95% CI, 0.65–0.81], p<0.00001; I2=0%). Conclusion: Within one year of treatment with an SGLT-2 inhibitor, the composite of cardiovascular passing with cardiovascular breakdown hospitalization, all-cause mortality, cardiovascular mortality, and cardiovascular breakdown hospitalization was significantly reduced.